maaf email atau password anda salah

People Think I’m Crazy

Monday, October 4, 2021

Airlangga University’ Merah Putih vaccine research team led by Prof. Fedik Abdul Rantam has been making rapid headway in the development of the country’s own Covid vaccine together with Biotis Pharmaceutical Indonesia. The vaccine is set to enter the first phase of the human clinical trial in the fourth week of October.

arsip tempo : 173221200785.

Head of Airlangga University’s (Unair) Merah Putih Vaccine Research Team, Fedik Abdul Rantam, at the university’s Research for Vaccine Technology Development Laboratory of the Institute of Tropical Disease, in Surabaya, East Java, September 22. Unair’s Merah Putih vaccine research team together with Biotis Pharmaceutical Indonesia is developing an inactivated virus-based Covid-19 vaccine which has now entered the second phase of preclinical testing. Tempo/Aris Novia Hidayat . tempo : 173221200785.

IN the midst of skyrocketing Covid-19 cases in June till August, Fedik Abdul Rantam, the leader of the Merah Putih vaccine research team from the Airlangga University (Unair) was busy traveling back and forth between Surabaya in East Java, and Biotis Pharmaceuticals’ head office in Gunung Sindur, Bogor, West Java. Biotis, Unair’s partner in the vaccine development, had just set up a biosafety level 3 (BSL-3) laboratory to conduct the

...

Subscribe to continue reading.
We craft news with stories.

For the benefits of subscribing to Digital Tempo, See More

The Best Choice

Rp 54.945/Month

Active for 12 Months, Rp 659.340

  • *You Save -Rp 102.000
  • *Guaranteed update of up to 52 Editions of Tempo Magazine

Rp 64.380/Month

Active Every Month Cancel Anytime

  • *Free for the first month if using a Credit Card

See Other Packages

Already a Subscribed? Log in here
To receive daily news by Email, Sign up for Tempo ID.

More Articles

More exclusive contents

  • November 18, 2024

  • November 11, 2024

  • November 4, 2024

  • October 28, 2024

Independent journalism needs public support. By subscribing to Tempo, you will contribute to our ongoing efforts to produce accurate, in-depth and reliable information. We believe that you and everyone else can make all the right decisions if you receive correct and complete information. For this reason, since its establishment on March 6, 1971, Tempo has been and will always be committed to hard-hitting investigative journalism. For the public and the Republic.

Login Subscribe